Compare TLIH & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TLIH | RNAZ |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | Singapore | United States |
| Employees | 62 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 8.0M |
| IPO Year | N/A | 2021 |
| Metric | TLIH | RNAZ |
|---|---|---|
| Price | $4.20 | $7.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 5.2K |
| Earning Date | 05-01-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $0.32 |
| 52 Week High | $7.00 | $20.99 |
| Indicator | TLIH | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 97.39 | 30.71 |
| Support Level | $0.38 | $6.08 |
| Resistance Level | N/A | $9.37 |
| Average True Range (ATR) | 0.39 | 0.45 |
| MACD | 0.45 | -0.10 |
| Stochastic Oscillator | 87.35 | 0.00 |
Ten-League International Holdings Ltd is a Singapore-based provider of turnkey project solutions. Its business consists of sales of heavy equipment and parts, heavy equipment rental and provision of engineering consultancy services to port, construction, civil engineering and underground foundation industries. It currently conducts its operations through its wholly-owned subsidiaries. The equipment it provides is organized into four categories based on their functions and application scenarios, namely, foundation equipment, hoist equipment, excavation equipment and port machinery. The company operates in Singapore and Other International Countries.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.